|Table of Contents|

Comparison of maintenance therapy efficacy between S-1 and capecitabine in patients with metastatic nasopharyngeal carcinoma benefiting from first-line chemotherapy

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 01
Page:
62-65
Research Field:
Publishing date:

Info

Title:
Comparison of maintenance therapy efficacy between S-1 and capecitabine in patients with metastatic nasopharyngeal carcinoma benefiting from first-line chemotherapy
Author(s):
FANG Fei; YUAN Hao; WEI Yan
Cancer Prevention and Control Centre,the Eighth Affiliated Hospital of Guangxi Medical University(the People's Hospital of Guigang),Guangxi Guigang 537100,China.
Keywords:
nasopharyngeal carcinoma; maintenance treatment; S-1; capecitabine
PACS:
R739.62
DOI:
10.3969/j.issn.1672-4992.2023.01.010
Abstract:
Objective:To observe the clinical efficacy,safety and benefit of S-1 and capecitabine maintenance treatment for patients with metastatic nasopharyngeal carcinoma after first-line chemotherapy.Methods:Retrospective analysis was performed on 91 patients with metastatic nasopharyngeal carcinoma who had received 4~6 cycles of first-line chemotherapy and had clinical benefits in our hospital from January 2016 to December 2019.26 patients chose to observe after the first-line chemotherapy,31 patients used S-1 maintenance therapy,and 34 patients used capecitabine maintenance therapy.The effect of maintenance therapy was evaluated.The efficacy of S-1 and capecitabine maintenance therapy as well as the adverse reactions were compared and the clinical indicators of possible benefits was screened.Results:Patients in the S-1 and capecitabine groups had significantly longer median PFS compared with the observation group(16.9 months,17.1 months vs 6.9 months,P＜0.001).There was no significant difference in PFS between S-1 group and capecitabine group.Adverse reactions of the maintenance treatment group were mainly leukopenia,anemia,thrombocytopenia,mucositis,hand and foot syndrome,rash,nausea and vomiting,and liver damage,which were mostly in grade 0-2 without grade 4 adverse reactions.The incidence of oropharyngeal mucositis in S-1 group was higher than that in capecitabine group,but the difference was not statistically significant.The incidence of hand-foot syndrome in the capecitabine group was higher than that in the S-1 group(P＜0.05).Univariate analysis showed that tumor lesions could continue to shrink in maintenance therapy after first-line chemotherapy,which was an independent prognostic factor for PFS prolongation.Conclusion:Both S-1 and capecitabine can be used as maintenance therapy in patients with metastatic nasopharyngeal carcinoma,which helps to improve PFS and the adverse reactions can be acceptable.

References:

[1]陈晓钟，李金高，林少俊，等.转移性鼻咽癌治疗专家共识［J］.中华放射肿瘤学杂志,2018,27(1):23-28. CHEN XZ,LI JG,LIN SJ et al.Expert consensus on the treatment of metastasis nasopharyngeal carcinoma［J］.Chinese Journal of Radiation Oncology,2018,27(1):23-28.
[2］YANG YP,QU S,LI JG,et al.Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma(CAPTAIN-1st):a multicentre,randomised,double-blind,phase 3 trial［J］.The Lancet Oncology,2021,22(8):1162-1174.
[3]廖恺，郑荣辉，冯建辉，等.初诊转移性鼻咽癌一线治疗后维持治疗研究［J］.实用医学杂志,2020,36(14):1929-1933. LIAO K,ZHENG RH,FENG JH,et al.Study of maintenance therapy after firstline treatment of patients with newly diagnosed metastatic nasopharyngeal carcinoma［J］.The Journal of Practical Medicine,2020,36(14):1929-1933.
[4]许曼，柴广金，石梅，等.卡培他滨维持治疗局部晚期鼻咽癌的回顾性研究［J］.中国肿瘤临床,2020,47(10):507-512. XU M,CHAI GJ,SHI M,et al.Capecitabine maintenance in the treatment of locally advanced nasopharyngeal carci-noma:a retrospective study［J］.Chinese Journal of Clinical Oncology,2020,47(10):507-512.
[5]SCOTT K,JOELJ,FADI S,et al.Cost-effectiveness of maintenance capecitabine and bevacizumab for metastatic colorectal cancer［J］.JAMA Oncology,2019,5(2):236-242.
[6]WANG X,WANG S,HUANG H,et al.Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment:The SYSUCC-001 randomized clinical trial［J］.JAMA,2021,325(1):50-58.
[7］JORDAN W,WILDFANG I,WELKOBORSKY H,et al.TPF induction therapy with radioimmunochemotherapy for the treatment of head and neck cancer［J］.Journal of Clinical Oncology,2009,27(15):7021-7021.
[8]张凯，杨峥，杨荣松，等.替吉奥胶囊与卡培他滨单药治疗老年晚期鼻咽癌的临床疗效比较［J］.肿瘤基础与临床,2017,39(05):31-34. ZHANG K,YANG Z,YANG RS,et al.Comparison of S-1 and capecitabine as monotherapy in the elderly patients with advanced nasopharyngeal carcinoma［J］.Journal of Basic and Clinical Oncology,2017,39(05):31-34.
[9］HAN SK,KIM HR,GM KIM,et al.The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma［J］.Cancer Chemotherapy & Pharmacology,2012,70(4):539-546.
[10]魏敏，雷勇，邵成泽，等.替吉奥在一线化疗后晚期鼻咽癌患者维持治疗中的疗效观察［J］.现代肿瘤医学,2018，26(02)：197-201. WEI M,LEI Y,SHAO CZ,et al.The clinical effects of S-1 on the maintenance therapy of advanced nasopharyngeal carcinoma patients after first-line treatment［J］.Modern Oncology,2018，26(02)：197-201.
[11]GUO Q,CHEN M,XU H,et al.Oral maintenance chemotherapy using S-1/capecitabine in metastatic nasopharyngeal carcinoma patients after systemic chemotherapy:A single-institution experience ［Corrigendum］［J］.Cancer Management and Research,2020,12:2365-2366.
[12]潘琦津，龚建忠，韦燕.转移性鼻咽癌维持治疗研究现状及进展［J］.现代肿瘤医学,2018，26(21):3505-3508. PAN QJ，GONG JZ，WEI Y.Maintenance therapy for metastatic nasopharyngeal carcinoma ［J］.Modern Oncology,2018，26(21):3505-3508.
[13]林燕峰，周玲玲，马慧敏.晚期鼻咽癌患者维持治疗中血浆EB病毒DNA水平变化的意义［J］.中国肿瘤临床与康复,2014，21(7):812-813. LIN YF,ZHOU LL,MA HM.Significance of plasma EB virus DNA level changes in patients with advanced nasopharyngeal carcinoma during maintenance treatment［J］.Chinese Journal of Clinical Oncology and Rehabilitation,2014,21(7):812-813.
[14]杨慧，陆颖，黄海欣，等.转移性鼻咽癌一线化疗后替吉奥维持治疗的多中心随机对照研究［J］.中国肿瘤临床,2021,48(1):25-29. YANG H,LU Y,HUANG HX,et al.S-1 maintenance therapy after first-line chemotherapy for metastatic nasopharyngeal carcinoma:a multicenter,randomized,controlled study［J］.Chinese Journal of Clinical Oncology,2021,48(1):25-29.

Memo

Memo:
广西贵港市科学研究与技术开发项目（编号：贵科攻1908021）;广西贵港市科技计划项目（编号：贵科攻2000036）
Last Update: 2022-11-30